Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536827 | 1.00 | PTGS1 (0.46) | PTGS1SLC6A2SLC6A4CHRM4KCNH2 | |
| SCHEMBL5535342 | 0.90 | SERPINE1 (0.38) | PTGS1SLC6A2SLC6A4CHRM4KCNH2 | |
| SCHEMBL5535348 | 0.90 | SERPINE1 (0.38) | PTGS1SLC6A2SLC6A4CHRM4KCNH2 | |
| SCHEMBL5539485 | 0.89 | KMT2A (0.38) | PTGS1SLC6A2SLC6A4KCNH2CYP3A4 | |
| SCHEMBL5539491 | 0.89 | KMT2A (0.38) | PTGS1SLC6A2SLC6A4KCNH2CYP3A4 | |
| SCHEMBL5540765 | 0.85 | CYP3A4 (0.34) | PTGS1SLC6A2SLC6A4CHRM4CYP3A4 | |
| SCHEMBL5540771 | 0.85 | CYP3A4 (0.34) | PTGS1SLC6A2SLC6A4CHRM4CYP3A4 | |
| SCHEMBL58326 | 0.84 | PTGS1 (0.44) | PTGS1SLC6A2SLC6A4CHRM4KCNH2 | |
| SCHEMBL58327 | 0.84 | PTGS1 (0.44) | PTGS1SLC6A2SLC6A4CHRM4KCNH2 | |
| SCHEMBL2951490 | 0.83 | PTGS1 (0.57) | PTGS1SLC6A2SLC6A4CHRM4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PTGS1 3838/4885SLC6A2 3396/4885SLC6A4 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.